Skip to main content

Table 4 The efficacy of concurrent chemoradiotherapy in previously reported phase II/III randomized controlled trials

From: Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis

Study Number CRT regimen mPFS PFS rate (%) mOS OS rate (%) ORR LCR (%)
(months) 1-yr 2-yr (months) 1-yr 2-yr (%) 1-yr 2-yr Overall
RTOG 9410 [5] 195 RT + VP NR NR NR 17 61.5 37.4 70.0 NR NR 70
187 RT + EP NR NR NR 15.6 60.9 31.6 65.0 NR NR 71
RTOG 0617 [41] 151 LDR + PC 11.8 49.2 29.1 28.7 80.0 57.6 NR 83.7 69.3 NR
107 HDR + PC 9.8 41.2 21.4 20.3 69.8 44.6 NR 75.2 61.4 NR
137 LDR + PC + Cet 10.8 44.3 24.2 25 76.2 56.3 NR 77.8 61.8 NR
100 HDR + PC + Cet 10.7 46.3 27.5 24 71.1 50.1 NR 82.4 69.3 NR
PROCLAIM [42] 283 RT + PP 14.1 NR NR 26.8 76.0 52.0 35.9 NR NR 62.7
272 RT + EP 9.8 NR NR 25 77.0 52.0 33.0 NR NR 54.2
CAMS [43] 95 RT + EP 14 56.8 29.5 23.3 74.1 48.4 73.7 NR NR NR
96 RT + PC 12 50 17.7 20.7 80.2 43.8 64.6 NR NR NR
WJOG5008L [44] 54 RT + SP 14.8 55.6 29.6 40.9 87.0 75.6 76.9 NR 51 NR
54 RT + VP 12.3 53.7 18.5 39 87.0 68.5 80.8 NR 28 NR
  1. CRT Chemoradiotherapy, RT Radiotherapy, LDR Low dose radiation, HDR High dose radiation, VP Vinblastine plus cisplatin, EP Etoposide plus cisplatin, PC Paclitaxel plus carboplatin, Cet Cetuximab, PP Pemetrexed plus cisplatin, SP S1 plus cisplatin, NR Not reported, PFS Progression-free survival, mPFS Median progression-free survival, OS Overall survival, mOS Median overall survival, ORR Objective response rate, LCR Local control rate, yr Year